Your browser doesn't support javascript.
loading
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Sugisaka, Jun; Toi, Yukihiro; Taguri, Masataka; Kawashima, Yosuke; Aiba, Tomoiki; Kawana, Sachiko; Saito, Ryohei; Aso, Mari; Tsurumi, Kyoji; Suzuki, Kana; Shimizu, Hisashi; Ono, Hirotaka; Domeki, Yutaka; Terayama, Keisuke; Nakamura, Atsushi; Yamanda, Shinsuke; Kimura, Yuichiro; Honda, Yoshihiro; Sugawara, Shunichi.
Afiliación
  • Sugisaka J; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Toi Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Taguri M; Department of Data Science, Yokohama City University school of Data Science, Yokohama, Japan.
  • Kawashima Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Aiba T; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Kawana S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Saito R; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Aso M; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Tsurumi K; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Suzuki K; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Shimizu H; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Ono H; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Domeki Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Terayama K; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Nakamura A; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Yamanda S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Kimura Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Honda Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
JMA J ; 3(1): 58-66, 2020 Jan 15.
Article en En | MEDLINE | ID: mdl-33324776
INTRODUCTION: Immune checkpoint inhibitors (ICIs) can lead to immune-related adverse events (irAEs). A correlation between the development of irAEs and efficacy has been suggested; however, it is unclear whether there is a relationship between programmed death ligand 1 (PD-L1) expression and the development of these events. METHODS: We performed a retrospective study of advanced or metastatic non-small cell lung cancer (NSCLC) patients who were treated with pembrolizumab monotherapy at our institution between May 2015 and April 2018 (n = 44). Patients were categorized into two groups, specifically those with irAEs (irAE group) or without (non-irAE group), and we evaluated the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Predictors of irAEs were examined by multivariate analysis. RESULTS: irAEs of any grade occurred in 31 (70.5%) patients. The median PFS was 10.9 months in the irAE group versus 3.7 months in the non-irAE group (P < 0.001). ORR and DCR were also higher in the irAE group than in the non-irAE group. Furthermore, high PD-L1 expression (≥50%) was a predictive factor of irAE based on logistic regression (P = 0.004). CONCLUSIONS: In patients with advanced NSCLC treated with pembrolizumab monotherapy, ORR, DCR, and PFS were significantly better in the irAE group than in the non-irAE group. High PD-L1 expression, at the time of pretreatment, was identified as an independent predictor of irAE development. We believe that more careful management of irAEs for individuals with high PD-L1 expression is needed to improve clinical benefits. Further, PD-L1 expression might be useful for ICI risk management.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JMA J Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JMA J Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón